Amundi’s Amicus Therapeutics FOLD Stock Holding History

Amundi’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,627	Closed	-$371K	–	2112
2026 Q1	$371K	Buy	+25,627	New	+$367K	﹤0.01%	1666
2022 Q4	–	Sell	-12,280	Closed	-$133K	–	1932
2022 Q3	$133K	Hold	12,280	–	–	﹤0.01%	1514
2022 Q2	$135K	Hold	12,280	–	–	﹤0.01%	1405
2022 Q1	$111K	Hold	12,280	–	–	﹤0.01%	1457
2021 Q4	$122K	Sell	12,280 -2,272	-16%	-$25.3K	﹤0.01%	1543
2021 Q3	$139K	Sell	14,552 -2,203	-13%	-$22.5K	﹤0.01%	1484
2021 Q2	$162K	Buy	+16,755	New	+$164K	﹤0.01%	1420

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Amundi's FOLD Position: Q2 2026 in Review

Amundi sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 25,627 shares — an estimated $371K sold.

Amundi first reported a position in FOLD in Q2 2021 and held it in 7 quarters. The position peaked at $371K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Amundi reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Amundi sold 25,627 Amicus Therapeutics shares in Q2 2026, an estimated $371K.
Amundi first reported a position in Amicus Therapeutics in Q2 2021 and held it in 7 quarters.
Amundi's Amicus Therapeutics position peaked at $371K in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.